

| Drug common name | CELGOSIVIR |
| INN | celgosivir |
| Description | Celgosivir, in development by Migenix for the treatment of hepatitis C virus (HCV) infection, is an oral prodrug of the natural product castanospermine that inhibits alpha-glucosidase I, an enzyme that plays a critical role in viral maturation by initiating the processing of the N-linked oligosaccharides of viral envelope glycoproteins. Celgosivir is well absorbed in vitro and in vivo, and is rapidly converted to castanospermine. Celgosivir has a novel mechanism of action (preventing the glycosylation of viral proteins by the host), and demonstrates broad antiviral activity in vitro.
|
| Classification | Small molecule |
| Drug class | antivirals: glucosidase inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCCC(=O)O[C@H]1CN2CC[C@H](O)[C@@H]2[C@@H](O)[C@@H]1O |
| PDB | — |
| CAS-ID | 121104-96-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2110737 |
| ChEBI ID | — |
| PubChem CID | 60734 |
| DrugBank | — |
| UNII ID | 895VG117HN (ChemIDplus, GSRS) |
